Levonorgestrel correlates with less weight gain than other progestins during hormonal replacement therapy in Turner Syndrome patients

Autor: Ieda Therezinha do Nascimento Verreschi, Magnus R. Dias-da-Silva, Patrícia Teófilo Monteagudo, Andréia Latanza Gomes Mathez
Rok vydání: 2019
Předmět:
Endocrine reproductive disorders
Adult
endocrine system
Medroxyprogesterone
Adolescent
medicine.drug_class
medicine.medical_treatment
Population
lcsh:Medicine
Physiology
Turner Syndrome
030209 endocrinology & metabolism
Levonorgestrel
Weight Gain
Article
Body Mass Index
03 medical and health sciences
Young Adult
0302 clinical medicine
Turner syndrome
medicine
Humans
lcsh:Science
education
Author Correction
Retrospective Studies
education.field_of_study
030219 obstetrics & reproductive medicine
Multidisciplinary
business.industry
lcsh:R
Estrogen Replacement Therapy
Hormone replacement therapy (menopause)
medicine.disease
Cross-Sectional Studies
Treatment Outcome
Contraceptive Agents
Hormonal
lcsh:Q
Female
medicine.symptom
Progestins
business
Hormonal therapies
Weight gain
Progestin
Dyslipidemia
medicine.drug
Zdroj: Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
ISSN: 2045-2322
Popis: Turner Syndrome (TS) is associated with an increased risk of cardiovascular and metabolic complications. Furthermore, TS women need hormone replacement therapy (HRT), of which progestins can influence body weight. We aimed to analyze the metabolic and weight profile in a cohort of 111 TS women. They started receiving estrogen at 15.8 (±3.6) years old, with no change in hypertension, dysglycemia, and dyslipidemia incidence but with a tendency to increase overweight (p = 0.054). As the first used type of progestin, most had received cycles of 10 days per month of medroxyprogesterone (MPA) or levonorgestrel (LNG), then shifted to micronized progesterone (MP), which has currently become the most used one. By multiple linear regression analysis, we found that the prolonged use of MPA, LNG, or MP showed no metabolic change except for weight gain. The percentage of annual BMI increment was positive for all progestins used in TS women (MPA 2.2 ± 2.2; LNG 0.2 ± 1.2; and MP 2.2 ± 2.6 kg/m2), but LNG seemed to best prevent on weight gain over time (p 0.05). In conclusion, metabolic comorbidities are prevalent in TS even before the HRT regimen, and LNG performed better on less weight gain than MPA and MP in our cohort of the TS population.
Databáze: OpenAIRE
Externí odkaz: